ATAlexandros Tsakalidis

Alexandros Tsakalidis

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alexandros Tsakalidis has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Management of low rectal gastrointestinal stromal tumor with neoadjuvant therapy and transanal excision: a rare case report and review of the literature

    by Christopher Kosmidis, Konstantinos Sapalidis, Alexandros Tsakalidis, Stefanos Atmatzidis, Nikolaos Michalopoulos, Georgios Koimtzis, Georgia Karayannopoulou, Sofia Lypiridou, Nikolaos Varsamis, Georgios Kouklakis, et al.

    Background: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. However, rectal GISTs represent only 5% of this category. We report a case of a rectal GIST treated with local excision after neoadjuvant therapy. Case presentation: A 41-year-old male patient presented with anal bleeding. Colonoscopy revealed a mass located 5 cm from the anal verge. Histological examination showed a GIST with immunohistochemical positivity for CD117 and CD34. Transanal local excision was performed after neoadjuvant therapy. Conclusion: Neoadjuvant immunotherapy for GISTs with unfavorable localization may facilitate local excision and avoid complications of more demanding operations.


  • Open Access

    Transformation of ALK expression and PD-L1 0% to PD-L1 90% only after surgery: the need for rebiopsy in lung cancer patients

    by Christoforos Kosmidis, Georgios Koimtzis, Dimitrios Giannakidis, Nikos Tteralli, Stylianos Mantalovas, Alexandros Tsakalidis, Konstantina Tsopouridou, Stefanos Atmatzidis, Lazaros Liavas, Paul Zarogoulidis

    Lung cancer is still diagnosed at a late stage although novel diagnostic techniques are in use. However, as pharmacogenomics have evolved novel targeted therapies either with tyrosine kinase inhibitors or immunotherapy can be currently used as daily treatment. We present the case of a woman with anaplastic lymphoma-positive expression and programmed death-ligand 1 (PD-L1) 0% score upon diagnosis who underwent therapeutic surgery and represented PD-L1 90% expression, however, without anaplastic lymphoma kinase expression. Transformation of the tumor or new tumor is a question to be answered for this patient and possibly we should try and direct rebiopsies for this group of targeted therapy patients.


  • Open Access

    Melanoma from Molecular Pathways to Clinical Treatment: An Up to Date Review

    by Christoforos Kosmidis, Sofia Baka, Konstantinos Sapalidis, Nick Mixalopoulos, Stefanos Atmatzidis, Harilaos Koulouris, George Anthimidis, Nick Varsamis, Paul Zarogoulidis, Yan-Gao Man, et al.

    Skin cancer is divided to melanoma and non-melanoma. Melanoma occurs due to deregulation of melanocytes. Melanoma is frequent in Caucasian population. During the last decade there is an increase in melanoma and in many cases there is a diagnostic challenge. Moreover; choosing the right treatment is a challenge for many patients. Malignant melanoma is known to be a lethal disease due to its aggressive capacity for metastasis and resistance to therapy. In the last decade, considerable efforts have gone into development of an effective immunotherapy for treatment of melanoma. The combination of macrophage activation and other treatments such as immunotherapy, surgery, chemotherapy, and radiotherapy, may provide an effective and comprehensive anti-melanoma strategy.